Varizellen-Zoster-Lebendimpfung bei älteren Patienten

Frage: Ist eine VZV-Lebendimpfung für ältere Patienten, ggf. nur seronegative, sinnvoll?

Literatur

• 1 National Institute of Infectious Diseases .The Jordan report: accelerated development of vaccines. www.niaid.nih.gov/publications/jordan/
• 2 Mc Gregor R. Herpes zoster, chickenpox and cancer in general practice.  Br Med J. 1957;  1 84
• 3 Takashi M. et al . Live vaccine used to prevent the spread of varicella in children in hospital.  Lancet. 1974;  2 228-234
• 4 Lawrence R. et al . Risk of Zoster after vaccination of children with leucemia.  New Engl J Med. 1988;  318 543-548
• 5 Berger R. et al . Enhancement of varicella-zoster-specific immune response in the elderly by boosting with varicella vaccine.  J Infect Dis. 1984;  149 647
• 6 Berger R. et al . A dose response study of live attenuated varicella-zoster virus (OKA strain) vaccine administered to adults 55 years of age and older.  J Infect Dis. 1998;  178 (Suppl 1) 99-103
• 7 Hayward A R. et al . Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults.  Viral mmunol. 1994;  7 31-36
• 8 Levin M J. et al . Use of live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age or older. Duration of booster effect.  J Infect Dis. 1998;  178 (Suppl 1) 109-112

Autor